The “BSL3 Research and Analysis Laboratory” is equipped with the most updated laboratory facility and instruments in the hope to provide immediate diagnosis in confronting novel infectious diseases. Our short-term goal is to provide accurate experimental data for evaluation of prophylactic/ therapeutic strategies and diagnosis methods against BSL-3 pathogens. Our long-term goal is to integrate a scientific team from basic researchers and clinical specialties, to cultivate talents specialized in life-threating infectious diseases, and to strengthen collaboration with national centers of disease control, which will help us to have a more immediate response to emerging infectious diseases to protect national health and maintain social economic development.

The “BSL3 Research and Analysis laboratory” isolated the first SARS-CoV-2 virus in Taiwan in late January of 2020, and has isolated many clinical SARS-CoV-2 strains since then. The full-length genome sequences of these SARS-CoV-2 strains have been determined and deposited in the GISAID. These variant strains can be used to evaluate the spectrum of antiviral drugs, vaccines/therapeutic antibody and diagnostic kits. We will continue to provide services and to increase the scope of our service items to respond to the needs from the industry and academia.